Skip to main content

Identification of Risk - Clinical Trials



Potential Risks is an essential part because Clinical Trials projects tend to be time constrained, post huge technical challenges and suffer from adequate resources. Not all the risks are equally important, should focus on risks that can materially affect project objectives or uncertainty that matters. There are numbers of factors can be internal, such as available resources, skills level of human resources, funding availability, management approach, time constraints etc.

Risks also vary depending on the stakeholder: subjects, study team, sponsor, competent authorities, target population and that is why stakeholders education, awareness, engagement and support are critical success factors for project risk management. Organizational and stakeholder risk attitudes and risk tolerances must be explicitly identified and managed before and during the project.

Clinical Trials process may be divided into three main steps, each of these steps can be associated with number of more or less significant risks.

1.Pre Trial: Study concept, Protocol Design, Site selection, clinical trial Agreement signing procedure. From application to competent authorities to first subject enrollment.

2.Conduct Trial: From first subject enrollment to Data base lock, presents risks related to recruitment, non compliance with regulatory aspects, data quality.

3. Post Trial: statistical methodology, impact on target population or public health in general.

Risk Management Process includes Identify Risks, Qualitative risk analysis, Quantitative risk analysis, Risk Monitoring and control.

Identify Risk: Identify all knowable risks to project objectives, including both Threats and Opportunities.Post Project reviews and lesson learned, Assumption and constraints analysis, Checklist analysis, Prompt lists, Root cause analysis, Brainstorming, Delphi Techniques, Force field analysis, Questionnaires.

Qualitative Risk Analysis: Assessing probability (likelihood) and impact if it does occur. Define Priority and Impact. Derive High Prioritized Risks(Priority *Impact)

Quantitative Risk Analysis: Quantifies the possible outcome for the project. Determine which risk events warrants response and overall project risk. Using Monte Carlo Simulation or Latin Hypercube.

Plan Risk Responses: For Positive Risks- Enhance, Exploit, Share and Accept. for Negative Risks- Mitigate, Avoid, Transfer and Accept.

Risk Monitoring and Control: Risk Reassessment-Monitoring risks often results in new Risks. Risk Audit- Effectiveness of risk responses in dealing with their root causes and risk management process.

It is unlikely that you will have all of this information initially. Therefore, the risk identification process is iterative. Each project is different and requires the project manager to determine the appropriate inputs and frequency.
Who identifies the risks? Project managers, team members, internal and external stakeholders, sponsor, to name a few. Notice that the project manager does NOT identify risks by themselves, since they have a limited view of the total project.
Project managers seek to increase the level of project detail through progressive elaboration. The aim is to reduce uncertainty — to uncover what is not known, to clarify assumptions, and to make decisions that propel the project forward. As these activities occur, the understanding of future events and conditions change. Consequently, project managers must update their risk registers.
Pre-mortem. This method can be used before the project begins. The project manager tells a story to the project team, as though the upcoming project has been completed. The story includes details of what transpired with elements of success and challenge, but the project is described ultimately as a failure. The project team is asked to identify risks and how the risks could have been handled to drive success.
Post-mortem. The project manager can facilitate a post review of a project that has truly failed, to identify lessons learned.

Nominal group technique. The project manager identifies a category of risk such as external risks. The team is asked to write down risks for the category. The project manager asks each team member to identify a risk and continues the process until all risks are captured, typically on a white board or cling sheets. Members are asked to rank the risks. The project manager captures the rankings of each member and shares the results. The project manager moves to the next risk category and continues the process. This method minimizes groupthink.

Facilitated workshops. A facilitator, often the project manager, facilitates a structured workshop aimed at identifying risks.

Scenario analysis. Different combinations of significant risks are described. Team members are asked to analyze the dependencies and impact to the project. It is possible to quantify the risks and illustrate which risk categories have the greatest risk exposure.(What if)

Brainstorming. Meeting where team members identify risks. Participants  (including CRAs, MWs, CDMs) are asked to refrain from criticizing ideas.

Interviews. The project manager interviews internal and external stakeholders to identify risks. This method takes a lot of time.

Cause and effect diagrams (i.e., Ishikawa Diagrams or Fishbone Diagrams). This tool can be used to identify the factors that contribute to an effect. For example, the project manager may ask what may be contributing to delays in the schedule. Team members may identify factors such as human resource issues, poor testing, and lack of training.

SWOT analysis. SWOT is an acronym for strengths, weaknesses, opportunities, and threats. The SWOT method is often used for strategic planning, but it may be used for risk identification too. For example, a project manager may facilitate a SWOT session on a business process or system.

HAZOD. HAZOD stands for hazard and operability study, which is a comprehensive analysis of a process or system. The project manager or business analyst facilitates a workshop by first dividing the project or system design into components. The team reviews each component to identify risks, causes of risks, impacts, and responses to risks. (e.g. Investigational Products)

Delphi technique. Involves submitting, at least, two rounds of queries through surveys or questionnaires to selected stakeholders. For example, the first query could involve asking participants to identify risks. The second query could involve having the participants rank the identified risks. This method minimizes groupthink.

Affinity diagrams. This method can help groups to identify the categories of risks. Start by brainstorming risks. Then ask the team to organize the risks into groups such as requirements, design, development, and testing.

Prompt list. Use a generic list of risks to “prompt” team members to identify risks. For example, a project manager may ask team members to identify requirement risks and then design risks.

A prompt list is list of common risk categories that can be used to
framework for additional risk identification techniques. Prompt lists stimulate creative thinking and an excellent tool to use with brainstorming.

Prompt lists are the highest level of risk breakdown structure example
PESTLE (Political, Economic, Social, Technological, Legal, Environmental)
TECOP ( Technical, Environmental, Commercial, Operational, Political),
SPECTRUM (Socio-Cultural, Political, Economic, Competitive, Technology, Regulatory/Legal, Uncertainty, Market).

Example: Economic: Interest rates, currency, financial markets, cash flow. Social: Ethical failures, loss of people, fraud, strikes. Technological: Technology change, Technical processes, system integrity, system availability. Operational: Fire, Natural hazards, patient injury, Investigational Product contamination, Investigational Product recall. Commercial: Internal procurement, suppliers and vendors, customer stability, contractual terms and conditions.

Checklist analysis. The project team uses a list of common risks — developed from previous similar projects — to help identify potential risks for a project. Beware — checklists are not comprehensive. Ask what else may help or hinder your projects.

Failure modes and analysis. This tool helps to identify failure modes, effects of each failure, and ways to reduce the probability and impact of the each failure.

Documentation analysis. The project manager may work with team members to perform a formal review of project documents such as requirement documents, project planning documents, contracts, historical documents, and reports from external entities.

Assumption analysis. The project team digs a little deeper to determine whether assumptions are valid.

Identification of risks is best done part of overall project planning, listing risks as you proceed. Risk management process provide a way to learn whether your project is feasible-whether you should believe it is possible. A feeling of confidence, based on credible information, is a powerful determinant of success and risk information is key source of data.

Thanks
Smit Shah PMP, PMI-RMP
 

Comments

Popular posts from this blog

CORONIL exposing drug development process/approval in India?

CORONIL exposing drug development process/approval in India? CORONIL has launched in India from Patanjali and no formal authority is aware on this on 23 Jun 2020. Paid media showing live coverage of launching of CORNIL and friends and family members celebrated. Main stream media does not know anything about clinical trials or drug development process as we know their main focus would be on religions, Indo-Pak thats it. Hence main stream media did not ask any relevant questions to Baba ji who sits in laboratory with raw materials and as usual media did not involve any relevant panelist. On 23 Jun 2020 evening, AYUSH ministry finally informed (after launching and completing of this coverage )that this scientific study are not known to ministry and asked Patanjali to stop this advertisements of Ayurvedic drugs and are regulated under the provision of Drugs and Magic Remedies Act 1954 and rules thereafter and the directives issued by the central government in the wake of COVID

A Landmark Revolution: The I-SPY 2 Trial's Transformative Impact on Breast Cancer Treatment

Background: A Visionary Scientist's Mission: In the early 2000s, breast cancer was a relentless adversary, affecting millions of women worldwide. Dr. Laura Esserman, a distinguished oncologist, emerged as a beacon of hope in the battle against this formidable disease. Driven by her unwavering commitment to improving outcomes for breast cancer patients, she embarked on a mission to transform breast cancer care. Dr. Esserman's unique background as both a clinician and researcher provided her with invaluable insights. She saw the urgent need to revolutionize the traditional clinical trial model, which often moved at a snail's pace. Her vision and dedication paved the way for a groundbreaking study that would leave an indelible mark on the clinical trial industry. The I-SPY 2 Trial: An Innovation in Design : The I-SPY 2 Trial was no ordinary clinical trial; it was a groundbreaking endeavor characterized by its innovative and adaptive design. Here's why it became a game-cha

SPRINT in Clinical Trials Industry

Nobody knows everything: Nobody knows everything, not even the CEO. Need to incorporate information from many sources. Instead, the information is distributed asymmetrically across the team and across the company. In this process, we have got to gather it and make sense of it and asking the experts is the best and fastest way to do that. With luck, we chose our work because of bold vision. We want to deliver that vision to the world whether it is a message or service or an experience software or even a story or an idea. But bringing a vision to life is difficult. It I s always easy to get in endless emails, deadline that slip, meeting that burn up day, a long term projects based on questionable assumptions. It does not have to be that way. If there is any idea, big challenge and not quite enough time and if we could not prove that idea was viable in that time, then it switches to different projects/ideas. We need encouragement in Clinical Trial industry on experiment not only in th

Transforming Risk Management and Stakeholder Engagement in Clinical Trials: A PM's Journey

  ABC Pharmaceuticals, a pioneering biotech firm known for its cutting-edge research in therapeutic innovations. Amidst their quest for groundbreaking treatments, they encountered a pivotal juncture during a Phase IIb/III cardiovascular trial. Regulatory shifts, supply chain vulnerabilities, and safety concerns cast a shadow over their aspirations. This is the story of how the Clinical Project Manager, redefined risk management, embracing challenges as catalysts for innovation while transforming stakeholder conversations. ABC Pharmaceuticals, driven by innovation, harbored a risk-averse culture—prioritizing safety and efficacy without aggressively embracing uncertainties. CPM recognized the need for a paradigm shift. He envisioned risk not merely as a hurdle but as a potential driver of transformative change within the trial landscape. The Evolution of Risk Management: Identifying the Challenges: ABC Pharmaceuticals’ initial risk assessments identified potential disruptions: Evo

Unraveling the Challenges of Unstructured Site Management Organizations (SMOs) in India's Clinical Trial Sector with a Unified Approach

  Clinical research in India has witnessed substantial growth in recent years, with Site Management Organizations (SMOs) playing a pivotal role in conducting trials efficiently. However, challenges arise when dealing with unorganized SMOs, which lack regulatory oversight and financial transparency. This case study explores the issues stemming from such SMOs and offers a comprehensive strategy to mitigate risks and ensure successful clinical trials in India. Understanding the Unorganized SMO Landscape :  Insights into the Growth of Unorganized SMOs in India and the Reasons Behind Their Frequent Closure: The landscape of Site Management Organizations (SMOs) in India has witnessed exponential growth in recent years, with multiple SMOs often operating within a single research site. This proliferation can be attributed to several factors, primarily the absence of robust regulatory oversight and accountability mechanisms specific to SMOs in the clinical research ecosystem.  Lack of Regulator

The Impact of Genetic Differentiation Across Regions: The Case of Drug Responses and Clinical Trials

Genetic differentiation across regions can significantly impact how populations respond to drugs. Variations in genetic makeup mean that a medication might be effective for one group but less so, or even harmful, for another. This variability underscores the importance of tailored clinical trials and has implications for the recent CDSCO notification on waiving clinical trials. Here, we’ll explore examples where genetic differences have influenced drug efficacy and safety, highlighting the importance of considering these differences in drug approval processes. Warfarin and Genetic Variability Case Study: Warfarin is a widely used anticoagulant prescribed to prevent blood clots. The drug's dosing is highly individualized, and genetic variations play a crucial role in how patients metabolize it. Variants in the CYP2C19 gene and the VKORC1 gene influence Warfarin’s effectiveness and risk of bleeding. Genetic Differentiation:In populations of European descent, certain genetic variants

Virtual Clinical Trial: A complete Remote Concept

Virtual Industry revenues will reach to $7.2 billion globally by the end of 2017 as in Greenlight Insight’s latest report. Anticipating modest growth in the short term, expects the Virtual industry to grow into a major global marketplace by 2021, reaching $74.8 billion in global revenues. Virtual industry remarkably uses cases including Tourism, Education, Sales and Marketing, designing and sports coaching. How about on Clinical Trial Industry? Clinical Trial industry is facing crisis, nearly 80% of trials do not meet enrollment timelines, and these delays can amount to $8 million in lost revenues per day, according to one estimate by Cutting edge information. But now the industry is preparing to bet on new trend: Virtual Clinical Trials. Virtual Clinical Trials represent a relatively new method of collecting safety and efficacy data from clinical trial participants. Imaging few scenario on this. Patients do not travel to sites. Devices (it can be mobile, watch, glass) link to th

From Darkness to Light: The Stanford Prison Experiment and the Ethical Evolution of Modern Clinical Trials

Once upon a time, in the early 1970s, a young psychologist named Philip Zimbardo embarked on a groundbreaking experiment at Standford university that would forever change the way we look at human behavior and research ethics. It began with an ad in the classifieds.  Male college students needed for psychological study of prison life. $15 per day for 1–2 weeks.  More than 70 people volunteered to take part in the study, to be conducted in a fake prison housed inside Jordan Hall, on Stanford’s Main Quad. The leader of the study was 38-year-old psychology professor Philip Zimbardo. He and his fellow researchers selected 24 applicants and randomly assigned each to be a prisoner or a guard. Zimbardo encouraged the guards to think of themselves as actual guards in a real prison. He made clear that prisoners could not be physically harmed, but said the guards should try to create an atmosphere in which the prisoners felt “powerless.” The study began on Sunday, August 17, 1971. But no one knew

Six Sigma in Clinical Trials

Process improvement techniques increasingly have been applied outside manufacturing for examples software development and healthcare . I Concerns the potential use of lean and six sigma to improve the process involved in clinical research. Improving quality, avoiding delays and errors and speeding up the time to implementation of biomedical discoveries is primary objective. Reducing the time between biomedical research discoveries and their adoption into clinical practice requires increased co-ordination, systematic planning. Better co-ordination, timeliness, efficiency and value of clinical research can be achieved by applying the set of principles, practices and method represented by Lean and Six sigma. Lean thinking involves a set of principles, practices and methods or designing, improving and managing process. Lean process reflects the goal of continually reducing waste and improving work flow to efficiently produce a product or service that is received to be or high val